Puregon was launched in Denmark, Germany and the UK for ovulation induction in clomiphene-resistent anovulation and controlled ovarian hyperstimulation. Transfected Chinese hamster ovary cells with plasmids containing the genes encoding the α- and β-FSH subunits produced recFSH that was similar to uroFSH. In both cases (follitropin α and β) no antibody formation was detected, however, this form appeared to be more active than follitropin α in that there was a 25% greater pregnancy rate compared to uroFSH.

A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. 

Used as a component of infertility regimens to induce multiple follicular maturation and pregnancy in ovulatory women undergoing controlled ovarian hyperstimulation in ART programs such as in vitro fertilization (IVF).

A less-purified menotropins preparation (Repronex) containing higher amounts of extraneous urinary proteins previously was used for multiple follicular development and ovulation induction as part of an ART program or in women with functional anovulation (i.e., secondary to pituitary insufficiency and not due to primary ovarian failure); this preparation is no longer commercially available in the US.

The optimum controlled ovarian hyperstimulation regimen is controversial; individualize treatment decisions.

Women approved for treatment with gonadotropins must have ovaries that respond to FSH and LH stimulation; primary ovarian failure and pregnancy must be ruled out before initiating treatment with menotropins. (See Contraindications under Cautions.)